{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:19:35Z","timestamp":1793823575105,"version":"4.6.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate the clinical efficacy and adverse events (AEs) of apatinib salvage treatment for diffuse malignant peritoneal mesothelioma (DMPM) that has failed to respond to the recommended treatments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>27 patients with refractory DMPM were treated with apatinib at our center from April 2014 to October 2020, at the initial dose of 250 mg\/d. The dose was reduced to 125 mg\/d when serious adverse events (SAEs) occurred. 28-day was set as a treatment cycle. The frequency of follow up was once every 28 days. The efficacy evaluation was conducted according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria and the serum tumor markers before and after apatinib treatment. The safety assessment was performed with the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The primary endpoints were objective response rate (ORR) and disease control rate (DCR), and the secondary endpoints were AEs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The 27 patients completed a median treatment-cycle of 15.0, ranging from 5.1 to 39.4 cycles. At the median follow-up of 14.3 (4.8-51.8) months, median overall survival (OS) was 59.4 months, median apatinib-treatment-related survival (ATRS) was 14.0 (4.8-36.8) months. Complete response (CR) was observed in 0 case (0.0%), partial response (PR) in 4 cases (14.8%), stable disease (SD) in 12 cases (44.4%), and progression disease (PD) in 11 cases (40.7%). The ORR was 14.8%, and DCR was 59.3%. The median serum CA125 values before and after apatinib treatment were 32.9 (7.0-4592.4) U\/mL and 29.7 (6.1-4327.4) U\/mL, respectively (<jats:italic>P<\/jats:italic>=0.009). The common AEs were hypertension (6\/27; 22.2%), hand-foot syndrome (5\/27; 18.5%), albuminuria (4\/27; 14.8%), anemia (4\/27; 14.8%), leukopenia (4\/27; 14.8%), rash (2\/27; 7.4%), fatigue (2\/27; 7.4%), oral ulcers (2\/27; 7.4%), hoarseness (2\/27; 7.4%), nausea\/vomiting (2\/27; 7.4%), diarrhea (2\/27; 7.4%), headache (1\/27; 3.7%), and fever (1\/27; 3.7%). The incidence rate of grade III\/IV AEs was 16.2%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Apatinib is effective in treating refractory DMPM, with promising efficacy and acceptable safety.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.811800","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T06:21:35Z","timestamp":1656656495000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Adverse Events of Apatinib Salvage Treatment for Refractory Diffuse Malignant Peritoneal Mesothelioma: A Pilot Study"],"prefix":"10.3389","volume":"12","author":[{"given":"Zhi-Ran","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Dong","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He-Liang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1055\/a-1083-6962","article-title":"Diffuse Malignant Peritoneal Mesothelioma (DMPM) - a Rare Diagnosis","volume":"58","author":"Habbel","year":"2020","journal-title":"Z Gastroenterol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a009093","article-title":"Analysis of Current Trends in United States Mesothelioma Incidence","volume":"145","author":"Price","year":"1997","journal-title":"Am J Epidemiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2014_053","article-title":"Prognostic Factors Influencing Survival in 35 Patients With Malignant Peritoneal Mesothelioma","volume":"61","author":"Kaya","year":"2014","journal-title":"Neoplasma"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2008.09.010","article-title":"Cytoreductive Surgery and Intraperitoneal Chemotherapy for Peritoneal Mesothelioma","volume":"35","author":"Yano","year":"2009","journal-title":"Eur J Surg Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-010-0531-7","article-title":"Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy in Patients With Peritoneal Carcinomatosis of Colonic Origin: Outcomes After 7 Years' Experience of a New Centre for Peritoneal Surface Malignancies","volume":"12","author":"Bretcha","year":"2010","journal-title":"Clin Transl Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-3978-x","article-title":"Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: A Systematic Review and Meta-Analysis","volume":"22","author":"Helm","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-012-2264-z","article-title":"The Treatment of Peritoneal Carcinomatosis of Colorectal Cancer With Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Peroperative Chemotherapy (HIPEC) With Oxaliplatin: A Belgian Multicentre Prospective Phase II Clinical Study","volume":"19","author":"Hompes","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e318243555b","article-title":"Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) as a Maker for Malignant Vascular Tumors and Mesothelioma - Immunohistochemical Study of 262 Vascular Endothelial and 1640 Nonvascular Tumors","volume":"36","author":"Miettinen","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-529","article-title":"Safety and Pharmacokinetics of Novel Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitor YN968D1 in Patients With Advanced Malignancies","volume":"10","author":"Li","year":"2010","journal-title":"BMC Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.050310","article-title":"Metabolism and Pharmacokinetics of Novel Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitor Apatinib in Humans","volume":"41","author":"Ding","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.01.010","article-title":"Apatinib Exerts Anti-Tumour Effects on Ovarian Cancer Cells","volume":"153","author":"Ding","year":"2019","journal-title":"Gynecol Oncol"},{"key":"B12","article-title":"Apatinib Suppresses the Proliferation and Apoptosis of Gastric Cancer Cells via the PI3K\/Akt Signaling Pathway","volume":"24","author":"Jia","year":"2019","journal-title":"J BUON"},{"key":"B13","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12876-018-0870-3","article-title":"Apatinib Affect VEGF-Mediated Cell Proliferation, Migration, Invasion via Blocking VEGFR2\/RAF\/MEK\/ERK and PI3K\/AKT Pathways in Cholangiocarcinoma Cell","volume":"18","author":"Huang","year":"2018","journal-title":"BMC Gastroenterol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2174\/092986708783955446","article-title":"Molecular Targets and Targeted Therapies for Malignant Mesothelioma","volume":"15","author":"Palumbo","year":"2008","journal-title":"Curr Med Chem"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.585079","article-title":"Apatinib Mesylate Inhibits the Proliferation and Metastasis of Epithelioid Malignant Peritoneal Mesothelioma In Vitro and In Vivo","volume":"10","author":"Yang","year":"2020","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1538\/expanim.20-0119","article-title":"Establishment and Histopathological Study of Patient-Derived Xenograft Models and Primary Cell Lines of Epithelioid Malignant Peritoneal Mesothelioma","volume":"70","author":"Yang","year":"2021","journal-title":"Exp Anim"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3816\/CLC.2005.n.020","article-title":"Open-Label Study of Pemetrexed Alone or in Combination With Cisplatin for the Treatment of Patients With Peritoneal Mesothelioma: Outcomes of an Expanded Access Program","volume":"7","author":"Janne","year":"2005","journal-title":"Clin Lung Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21572","article-title":"Mesothelioma: Scientific Clues for Prevention, Diagnosis, and Therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2019.12.15","article-title":"Peritoneal Mesothelioma","volume":"9","author":"Alissa","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12967-018-1421-y","article-title":"Apatinib Exhibits Anti-Leukemia Activity in Preclinical Models of Acute Lymphoblastic Leukemia","volume":"16","author":"Deng","year":"2018","journal-title":"J Transl Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013105","article-title":"Apatinib for Salvage Treatment of Advanced Malignant Pleural Mesothelioma: A Case Report","volume":"97","author":"Du","year":"2018","journal-title":"Med (Baltimore)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.811800\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T06:21:37Z","timestamp":1656656497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.811800\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":21,"alternative-id":["10.3389\/fonc.2022.811800"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.811800","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,1]]},"article-number":"811800"}}